Mark Jit

45.4k total citations · 7 hit papers
355 papers, 14.2k citations indexed

About

Mark Jit is a scholar working on Epidemiology, Health and Infectious Diseases. According to data from OpenAlex, Mark Jit has authored 355 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Epidemiology, 125 papers in Health and 99 papers in Infectious Diseases. Recurrent topics in Mark Jit's work include Vaccine Coverage and Hesitancy (120 papers), Cervical Cancer and HPV Research (72 papers) and COVID-19 epidemiological studies (71 papers). Mark Jit is often cited by papers focused on Vaccine Coverage and Hesitancy (120 papers), Cervical Cancer and HPV Research (72 papers) and COVID-19 epidemiological studies (71 papers). Mark Jit collaborates with scholars based in United Kingdom, United States and Hong Kong. Mark Jit's co-authors include W. John Edmunds, Raymond Hutubessy, Marc Brisson, Philippe Beutels, Alex R. Cook, Kiesha Prem, Yot Teerawattananon, Rafael Mikolajczyk, Gianpaolo Scalia Tomba and Stefania Salmaso and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Mark Jit

345 papers receiving 13.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases

2008 1.9k citations Mark Jit, Philippe Beutels et al. profile →
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

2021 821 citations Olivier J. Wouters, Heidi J. Larson et al. profile →
Projecting social contact matrices in 152 countries using contact surveys and demographic data

2017 502 citations Kiesha Prem, Alex R. Cook et al. PLoS Computational Biology profile →
The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories

2021 236 citations Yang Liu, Mark Jit et al. BMC Medicine profile →
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?

2021 214 citations Mark Jit et al. profile →
Adjusting for Inflation and Currency Changes Within Health Economic Studies

2019 205 citations Hugo C. Turner, Yot Teerawattananon et al. profile →
Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination

2024 39 citations Edwin van Leeuwen, Stefan Flasche et al. The Lancet Regional Health - Europe profile →

Peers

Countries citing papers authored by Mark Jit

Since Specialization

Citations

This map shows the geographic impact of Mark Jit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Jit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Jit more than expected).

Fields of papers citing papers by Mark Jit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Jit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Jit. The network helps show where Mark Jit may publish in the future.

Co-authorship network of co-authors of Mark Jit

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Jit. A scholar is included among the top collaborators of Mark Jit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Jit. Mark Jit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An Introduction to Costing and the Types of Costs Used within Health Economic Studies 2025 ·PharmacoEconomics - Open ·Hugo C. Turner, (unknown), (unknown), (unknown), Saudamini Vishwanath Dabak, (unknown), Mark Jit, Yot Teerawattananon	0
2	Inequitable Distribution of Global Economic Benefits from Pneumococcal Conjugate Vaccination 2024 ·Vaccines ·(unknown), Fiona M. Russell, Mark Jit, Natalie Carvalho	2
3	Evaluating Scope and Bias of Population-Level Measles Serosurveys: A Systematized Review and Bias Assessment 2024 ·Vaccines ·Alyssa N. Sbarra, Felicity T. Cutts, Han Fu, (unknown), Dale A. Rhoda, Jonathan F Mosser, Mark Jit	3
4	Potential health and economic impact of paediatric vaccination using next-generation influenza vaccines in Kenya: a modelling study 2023 ·BMC Medicine ·Naomi R. Waterlow, (unknown), Jeanette Dawa, Edwin van Leeuwen, Simon R. Procter, Philipp Lambach, Joseph Bresee, (unknown), Rosalind M. Eggo, Mark Jit	9
5	“We usually see a lot of delay in terms of coming for or seeking care”: an expert consultation on COVID testing and care pathways in seven low- and middle-income countries 2023 ·BMC Health Services Research ·(unknown), (unknown), (unknown), (unknown), Titus Divala, Andrés G. Lescano, Mohammed Majam, (unknown), Auliya A. Suwantika, Marco Tovar, Pragya D. Yadav, (unknown), Anna Vassall, Mark Jit	3
6	Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries 2023 ·BMC Medicine ·Sarwat Mahmud, Ranju Baral, Colin Sanderson, Clint Pecenka, Mark Jit, You Li, Andrew Clark	13
7	Analyses of the return on investment of public health interventions: a scoping review and recommendations for future studies 2023 ·BMJ Global Health ·Hugo C. Turner, (unknown), Paul Revill, Waranya Rattanavipapong, (unknown), Justice Nonvignon, Mark Jit, Yot Teerawattananon	9
8	Assessing the impact of the 2018 Changchun Changsheng vaccine incident on childhood vaccination in China 2023 ·SHILAP Revista de lepidopterología ·Zhiyuan Hou, Xiaozhen Lai, Yang Liu, Mark Jit, Heidi J. Larson, Hai Fang	3
9	The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries 2023 ·BMJ Global Health ·Allison Portnoy, Rebecca A. Clark, Chathika K. Weerasuriya, Christinah Mukandavire, Matthew Quaife, Roel Bakker, Inés García Baena, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. White, Nicolas A. Menzies	10
10	Optimal health and economic impact of non-pharmaceutical intervention measures prior and post vaccination in England: a mathematical modelling study 2022 ·Royal Society Open Science ·Michael J. Tildesley, Anna Vassall, Steven Riley, Mark Jit, Frank Sandmann, Edward M. Hill, Robin N. Thompson, (unknown), John Edmunds, Louise Dyson, Matt J. Keeling	14
11	Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: a modelling study 2022 ·EClinicalMedicine ·(unknown), Xuelian Zhao, Shangying Hu, Meng Gao, Yang Liu, (unknown), You‐Lin Qiao, Mark Jit, Fanghui Zhao	12
12	Projections of human papillomavirus (HPV) vaccination impact in Ethiopia, India, Nigeria and Pakistan: a comparative modelling study 2021 ·BMJ Global Health ·Allison Portnoy, Kaja Abbas, Steven Sweet, Jane J. Kim, Mark Jit	12
13	Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries 2021 ·BMC Medicine ·Han Fu, Kaja Abbas, Petra Klepac, Kevin van Zandvoort, Hira Tanvir, Allison Portnoy, Mark Jit	11
14	Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic 2021 ·The Lancet Regional Health - Europe ·Mark Jit, (unknown), Martin McKee, Olivier J. Wouters, Philippe Beutels, Yot Teerawattananon	56
15	Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities 2021 ·Vaccine ·Di Liu, Kathy Leung, Mark Jit, Joseph T. Wu	7
16	Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era 2021 ·PLoS Computational Biology ·Kiesha Prem, Kevin van Zandvoort, Petra Klepac, Rosalind M. Eggo, Nicholas G. Davies, Alex R. Cook, Mark Jit	122
17	Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detection 2021 ·Philosophical Transactions of the Royal Society B Biological Sciences ·Thibaut Jombart, (unknown), (unknown), (unknown), Quentin J. Leclerc, Mark Jit, Stefan Flasche, Felix Greaves, Tom Ward, Rosalind M. Eggo, Emily Nightingale, Sophie Meakin, Oliver J. Brady, (unknown), Graham F. Medley, Michael Höhle, W. John Edmunds	12
18	Caregiver and service provider vaccine confidence following the Changchun Changsheng vaccine incident in China: A cross-sectional mixed methods study 2020 ·Vaccine ·(unknown), (unknown), Tracey Chantler, Xuan Zhang, Mark Jit, Kaiyi Han, Lance E. Rodewald, Fanxing Du, Hongjie Yu, (unknown), Heidi J. Larson	17
19	Controlling measles using supplemental immunization activities: A mathematical model to inform optimal policy 2014 ·Vaccine ·Stéphane Verguet, Mira Johri, Shaun K. Morris, Cindy L. Gauvreau, Prabhat Jha, Mark Jit	60
20	The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based Study 2011 ·PLoS ONE ·Albert Jan van Hoek, Anthony Underwood, Mark Jit, Elizabeth Miller, W. John Edmunds	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact